Navigation Links
Further breakthroughs for breast cancer patients

Researchers at the Tenovus Centre for Cancer Research at Cardiff University have made a breakthrough in breast cancer treatment that could help save the lives of women who become resistant to breast cancer drugs such as tamoxifen.

While drugs such as tamoxifen have been a huge success in treating breast cancer, for a significant proportion of sufferers the drugs either fail to work, or after an initial successful response the patient relapses as the cancer acquires or possesses resistance to the drug.

However the researchers have discovered that inhibiting the activity of a certain protein in the cancer could prevent or even reverse the resistance to tamoxifen. The researchers noticed that when breast cancer cells grown in the laboratory develop resistance to tamoxifen, they show a large increase in the activity of a protein known as Src and by stopping this activity resistance to tamoxifen can be prevented and even reversed.

Dr Stephen Hiscox of the Welsh School of Pharmacy, who led the research team and has just been appointed as one of the Cancer Research UK Cardiff University Research Fellows explained: We have previously shown that when breast cancer cells become resistant to medicines such as tamoxifen in the laboratory they become more aggressive with an invasive behaviour. These are characteristics that can be promoted by Src, a protein which we have recently shown to be more active in tamoxifen-resistant than tamoxifen-sensitive breast cancer cells.

As part of collaborative research between Tenovus and AstraZeneca, it was found that this aggressive, invasive behaviour could be reduced by treating the cells with a specific inhibitor of Src activity, AZD0530. Surprisingly, AZD0530 also made the tamoxifen-resistant cells sensitive to tamoxifen again. In addition, we found that co-treating the cells with a combination of tamoxifen and AZD0530 could actually prevent drug resistance occurring in the first place.

The Src inhibitor AZD0530 developed by AstraZeneca is currently in early clinical trials. If the results seen in the laboratory can be reproduced in the clinic, this approach could offer a substantial clinical benefit to a large number of women with breast cancer, as Professor Robert Nicholson, Director of the Tenovus Centre for Cancer Research, explains:

Whilst little is known about the mechanisms used by breast cancers to become resistant to common therapies such as tamoxifen, it remains a significant clinical problem. Therefore the ability to restore sensitivity to therapy, or to even prevent resistance arising in the first place, could be of huge benefit to a large number of breast cancer patients.


Contact: Lowri Jones
Cardiff University

Related biology news :

1. Further development of Water Framework Directive necessary
2. Male contraception breakthroughs to be presented, Seattle Sept. 27-28
3. Breast cancer cells have to learn to walk before they can run
4. Varying prevalence among ethnic groups of gene mutation that increases risk of breast cancer
5. CSHL scientists identify and repress breast cancer stem cells in mouse tissue
6. New study reveals for first time how BRCA1 mutations cause breast cancer
7. Purdue research finds similarities in dog, human breast cancer pre-malignant lesions
8. Cell response to stress signals predicts tumors in women with common pre-breast cancer
9. Breastfeeding boost IQ in infants with helpful genetic variant
10. Breast cancer research and inkjet tissue printing get NSF boost
11. Einstein researchers receive grants totaling $700,000 for innovative breast cancer research
Post Your Comments:
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
(Date:11/24/2015)... 24, 2015  Clintrax Global, Inc., a worldwide provider of clinical ... today announced that the company has set a new quarterly earnings ... on quarter growth posted for Q3 of 2014 to Q3 of ... Mexico , with the establishment of an ... --> United Kingdom and Mexico ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
Breaking Biology Technology: